October 26, 2018 Drug Utilization Review Board
»
Additional Item 1
Additional Item 1
»
1. Call to order
1. Call to order
»
2. Approval of minutes from July 27, 2018 (vote required)
2. Approval of minutes from July 27, 2018 (vote required)
»
3. New member introductions and terms
3. New member introductions and terms
»
4. Ethics policy refresher
4. Ethics policy refresher
»
5. Vice-chair election (vote required)
5. Vice-chair election (vote required)
»
6. New business (Part 1 of 2)
» - a. Androgenic agents b. Antibiotics, GI c. Antibiotics, topical d. Antibiotics, vaginal e. Antiemetics/Antivertigo agents f. Antifungals, oral g. Antifungals, topical h. Antihistamines, first generation i. Antiparasitics, topical j. Antipsychotics k. Antivirals, oral l. Antivirals, topical m. Bone resorption suppression and related agents n. Colony stimulating factors o. Cytokine and CAM antagonists
6. New business (Part 1 of 2) »
a. Androgenic agents b. Antibiotics, GI
c. Antibiotics, topical
d. Antibiotics, vaginal
e. Antiemetics/Antivertigo agents
f. Antifungals, oral
g. Antifungals, topical
h. Antihistamines, first generation
i. Antiparasitics, topical
j. Antipsychotics
k. Antivirals, oral
l. Antivirals, topical
m. Bone resorption suppression and related agents
n. Colony stimulating factors
o. Cytokine and CAM antagonists
»
Additional Item 2 - Additional Item 2
Additional Item 2
Additional Item 2
»
6. New business (Part 2 of 2) » - p. Epinephrine, self-injected q. GI motility, chronic r. Growth hormone s. Hepatitis C agents t. Hypoglycemics, incretin mimetics/enhancers u. Hypoglycemics, insulin and related agents v. Hypoglycemics, meglitinides w. Hypoglycemics, metformins x. Hypoglycemics, SGLT2 y. Hypoglycemics, TZD z. Immunomodulators, atopic dermatitis
aa. Macrolides/Ketolides
bb. Ophthalmics, glaucoma agents
cc. Opiate dependence treatments
dd. Pediatric vitamin preparations
ee. Penicillins
ff. Tetracyclines a. Aimovig / Antimigraine agents, other b. Mircera / Erythropoiesis stimulating proteins c. Osmolex ER / Antiparkinson’s agents d. Retacrit / Erythropoiesis stimulating proteins e. Roxybond / Analgesics, Narcotics short
6. New business (Part 2 of 2) »
p. Epinephrine, self-injected q. GI motility, chronic
r. Growth hormone
s. Hepatitis C agents
t. Hypoglycemics, incretin mimetics/enhancers
u. Hypoglycemics, insulin and related agents
v. Hypoglycemics, meglitinides
w. Hypoglycemics, metformins
x. Hypoglycemics, SGLT2
y. Hypoglycemics, TZD
z. Immunomodulators, atopic dermatitis
aa. Macrolides/Ketolides
bb. Ophthalmics, glaucoma agents
cc. Opiate dependence treatments
dd. Pediatric vitamin preparations
ee. Penicillins
ff. Tetracyclines
a. Aimovig / Antimigraine agents, other
b. Mircera / Erythropoiesis stimulating proteins
c. Osmolex ER / Antiparkinson’s agents
d. Retacrit / Erythropoiesis stimulating proteins
e. Roxybond / Analgesics, Narcotics short
»
Additional Item 3 - Additional Item 3
Additional Item 3
Additional Item 3
»
7. Executive work session
7. Executive work session
»
8. Announcements of drugs recommended for the Medicaid PDL (vote required)
8. Announcements of drugs recommended for the Medicaid PDL (vote required)
»
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Benzodiazepine anxiolytics and controlled sedative hypnotics ii. Diabetes disease management iii. Rheumatoid arthritis management b. Report on recent retrospective DUR intervention outcomes: i. Opioids during pregnancy ii. Polypharmacy iii. Stroke prevention c. Retrospective DUR proposals (vote required) i. Management of psychotropic drug in adults ii. Medication adherence
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Benzodiazepine anxiolytics and controlled sedative hypnotics
ii. Diabetes disease management
iii. Rheumatoid arthritis management
b. Report on recent retrospective DUR intervention outcomes:
i. Opioids during pregnancy
ii. Polypharmacy
iii. Stroke prevention
c. Retrospective DUR proposals (vote required)
i. Management of psychotropic drug in adults
ii. Medication adherence
»
Items 10, 12 & 13 » - 10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) a. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria b. Cytokine and CAM antagonists - addition of Olumiant criteria 12. Adjourn 13. Next meeting date: January 25, 2019
Items 10, 12 & 13 »
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) a. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria
b. Cytokine and CAM antagonists - addition of Olumiant criteria
12. Adjourn
13. Next meeting date: January 25, 2019
